ClinicalTrials.Veeva

Menu

Measurement of Renal Functional Reserve Change In Patients With SRC Before and After Laparoscopic Deroofing

O

ou tongwen

Status

Unknown

Conditions

Simple Renal Cyst

Treatments

Drug: 100 g of amino acids supplementation
Procedure: Laparoscopic deroofing

Study type

Interventional

Funder types

Other

Identifiers

NCT03259594
otw-20170804-01

Details and patient eligibility

About

Renal functional reserve may be improved in patients with simple renal cysts after laparoscopic deroofing.

Full description

Simple renal cysts (SRC) are the most frequent type of cystic renal disease. The prevalence rate of SRCs is about 10% and increases with age. Hypertension and decreased renal functions have been reported to occur more commonly among these patients with SRC and there are no clear guidelines for managing asymptomatic SRCs.Renal functional reserve (RFR) describes the capacity of the intact nephron mass to increase glomerular filtration rate(GFR) from baseline in response to stimuli (e.g., protein load).The investigators hypothesized that RFR may be improved in some patients with simple renal cysts after laparoscopic deroofing despite identical resting glomerular filtration rate (rGFR).The aim of this study is to examine whether there is improvement of RFR in patients with simple renal cysts after laparoscopic deroofing.

Enrollment

200 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥18
  2. Estimated GFR >30 mL/min/1.73m2
  3. Subjects who signed informed consent forms

Exclusion criteria

  1. Allergy to iothalamate, shellfish or iodine
  2. Use of metformin or amiodarone
  3. Inability to maintain a stable regimen of medications which affect GFR for > one week prior to participation (e.g. non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, angiotensin receptor blockers)
  4. Use of medications which directly affect elimination of creatinine (e.g. cimetidine and trimethoprim)
  5. Acute exacerbation of asthma or chronic obstructive pulmonary disease within 3 months requiring hospitalization or oral steroid therapy
  6. Inadequate intravenous access
  7. Severe anemia (Hct <21%)
  8. Acute kidney injury (rise in creatinine to ≥1.5 times the previous baseline or by ≥ 0.3 mg/dL on most recent labs prior to enrollment)
  9. History of contrast-induced nephropathy
  10. Hyperthyroidism
  11. Pheochromocytoma
  12. Sickle cell disease
  13. Urinary retention or incontinence
  14. Status post organ transplant
  15. Pregnancy or active breast feeding
  16. Cognitive impairment with inability to give consent
  17. Institutionalized status

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

endophytic group
Experimental group
Description:
participants are with endophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
Treatment:
Drug: 100 g of amino acids supplementation
Procedure: Laparoscopic deroofing
exophytic group
Sham Comparator group
Description:
participants are with exophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
Treatment:
Drug: 100 g of amino acids supplementation
Procedure: Laparoscopic deroofing

Trial contacts and locations

1

Loading...

Central trial contact

Zhenhua Shang, MD.; Hao Yan, MD.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems